Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Nasdaq9d
Novo Nordisk Expands $499 Wegovy Savings Offer To All Cash-paying Patients
(RTTNews) - Novo Nordisk (NVO) has expanded its $499 per month Wegovy savings program to include all cash-paying patients. Till now, the reduced price offer was only available with NovoCare pharmacy.
Yahoo Finance9d
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Until today, the $499-per-month offer for Wegovy ® was only available via the recently launched NovoCare ® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and ...
Yahoo Finance9d
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Until today, the $499-per-month offer for Wegovy ® was only available via the recently launched NovoCare ® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will ...